(Reuters) - U.S. drugmaker Eli Lilly and Co on Tuesday forecast a decline in earnings this year in line with Wall Street estimates, with results hurt by cheaper generic forms of its Zyprexa schizophrenia drug and Cymbalta depression treatment.
Lilly expects earnings, excluding special items, of $2.77 to $2.85 per share this year. Analysts, on average, expected $2.78 per share, according to Thomson Reuters I/B/E/S.
The Indianapolis drugmaker forecast revenue this year between $19.2 billion and $19.8 billion, also in line with analysts' expectations. The company early last year had projected revenue of $20 billion for 2014, but in October said it would be hard-pressed to achieve that goal because of devaluation of the yen and slower growth in emerging markets.
Lilly said it expects to achieve its goals of 2014 net income of $3 billion and operating cash flow of $4 billion.
(Reporting by Ransdell Pierson; Editing by Jeffrey Benkoe)
No comments:
Post a Comment